WATERTOWN, Mass. -- (BUSINESS WIRE) -- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company’s chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 shares of common stock of the Company outside of the Company’s stockholder approved equity incentive plan. The grant of this stock option was approved by the compensation committee of the board of directors on April 16, 2014 as an inducement material to Dr. Bhargava entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4). Dr. Bhargava joined the Company as chief medical officer on March 31, 2014. The stock option has an exercise price per share of $16.30, the closing price per share of Company’s common stock as reported by NASDAQ on April 16, 2014 and is scheduled to vest over a four-year period, subject to his continued service with the Company. Dr. Bhargava’s other compensation information is summarized in a Current Report on Form 8-K previously filed by the Company with the Securities and Exchange Commission.
This press release is a required notice under NASDAQ Listing Rule 5635(c)(4).
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.